On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research … Continue reading The ROS1ders Interview Dr. Ross Camidge (16-May-2019)
Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC
Yesterday the FDA has granted Priority Review for entrectinib for the treatment of ROS1-positive NSCLC and NTRK fusion-positive solid tumors. The FDA is expected to make a decision on approval by August 18, 2019. FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
I’m Janet Freeman-Daily, a cofounder of The ROS1ders. I’m writing this post in response to some of the comments we’ve seen recently in our private Facebook group “ROS1 Positive (ROS1+) Cancer.” Many of our members who have ROS1+ cancers take the targeted therapy crizotinib (Xalkori), a tyrosine kinase inhibitor (TKI). It was approved by the … Continue reading Thinking about a “drug vacation” from crizotinib? Read this first!
The new National Comprehensive Cancer Network (NCCN) Guidelines for non-small cell lung cancer (NSCLC) added lorlatinib as a ROS1 treatment option, after progression on crizotinib or ceritinib. This means most insurance should start covering lorlatinib for ROS1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (Version 2.2019) (subscription required, but … Continue reading NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC
Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case. They would like ROS1+ patients who have taking crizotinib to share the following information (no names): Demographic data (e.g., … Continue reading ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!